Ulrike Gerdemann

As a dedicated researcher at Harvard University, Ulrike Gerdemann has developed a specialized expertise in CAR-T cell therapy, gene therapy, immune cell profiling, hematopoietic stem cell correction, transplant immunology, immunotherapy, immune microenvironment, pediatric immunology. A representative example of their recent contribution is the study titled "Human OX40L–CAR-T _regs target activated antigen-presenting cells and control T cell alloreactivity", which offers critical insights into the dynamics of CAR-T cell therapy and gene therapy. Additional work such as "B-cell–directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates" further demonstrates their commitment to advancing knowledge in this domain.